Small-molecule inhibitors of HIV integrase (HIV IN) have emerged as a promising new class of antivirals for the treatment of HIV/AIDS. The compounds currently approved or in clinical development specifically target HIV DNA integration and were identified using strand-transfer assays targeting the HIV IN/viral DNA complex. The authors have developed a second biochemical assay for identification of HIV integrase inhibitors, targeting the interaction between HIV IN and the cellular cofactor LEDGF/p75. They developed a luminescent proximity assay (AlphaScreen™) designed to measure the association of the 80amino-acid integrase binding domain of LEDGF/p75 with the 163-amino-acid catalytic core domain of HIV IN. This assay proved to be quite robust (with a Z′ factor of 0.84 in screening libraries arrayed as orthogonal mixtures) and successfully identified several compounds specific for this protein-protein interaction. (Journal of Biomolecular Screening 2008:406-414) 
INTRODUCTION
T HE HIGH PREVALENCE OF RESISTANCE among treatmentexperienced HIV-positive patients underscores the continuing need to develop antiretroviral agents with novel mechanisms of action. An emerging class of new antiviral drugs targets HIV integrase (HIV IN). This enzyme inserts the proviral DNA into the chromatin of infected cells, 1 a step that is essential for virus replication. Inhibition of integrase has proven to be effective in both preclinical and clinical studies. 2 Although various steps in the HIV integration process may represent viable drug targets, so far, only the strand-transfer reaction has proven to be amenable to small-molecule intervention. Two strand-transfer inhibitors, raltegravir (MK-0518) and elvitegravir (GS-9137), are currently either marketed (MK-0518) or in late-stage clinical development (GS-9137). Mechanistically, strand-transfer inhibitors are thought to bind to the active site of HIV IN molecules that are engaged with proviral DNA ends and lock the HIV IN/DNA complex in a conformation that cannot interact with cellular DNA to complete the integration process. 3 Data from ongoing clinical trials using raltegravir or elvitegravir show that HIV IN-resistant mutants that developed can be cross-resistant to both drugs. 4 Second-generation strand-transfer inhibitors may also face a similar problem of cross-resistance and may not provide a significant advantage over current compounds. Therefore, new HIV IN inhibitors that can be used in combination therapy, or sequentially with raltegravir or elvitegravir, may require novel modes of action. This goal could be achieved through a number of mechanisms such as allosteric inhibition of the HIV IN active site, inhibition of the nuclear localization of the preintegration complex, or blockage of interactions between HIV IN and cellular cofactors required for the integration process. The paradigm of targeting both active and allosteric sites for HIV reverse transcriptase using nucleoside and nonnucleoside reverse transcriptase inhibitors has proven to be a highly successful strategy in HIV therapy and provides a strong rationale for exploring additional target sites on IN.
Recent experimental evidence suggests that the interaction between HIV IN and the LEDGF/p75 cellular cofactor may be a candidate target for small-molecule intervention. LEDGF/p75 is a transcriptional coactivator that normally functions as a cellular survival factor involved in the regulation of stress-related genes under proapoptotic conditions. 5 During HIV infection, LEDGF/ p75 is recruited as the dominant nuclear binding partner of HIV IN. 6, 7 The importance of LEDGF/p75 binding was first revealed by the discovery that a number of class II HIV IN mutants that retain catalytic activity but are defective for viral replication are also defective for LEDGF/p75 binding. [8] [9] [10] Further evidence supporting a role for LEDGF/p75 in HIV integration has come from RNAi knockdown of LEDGF/p75, which alters sites of HIV integration 11 and inhibits viral replication. 12 A similar phenotype is observed in LEDGF -/mouse cells transduced with HIV reporter constructs. 13 In addition, overexpression of the LEDGF/p75 integrase binding domain acts as a dominant negative inhibitor of HIV replication. 14 Although LEDGF/p75 is thought to target HIV integration to sites of active chromatin, other functions for LEDGF/p75 may include protection of HIV IN from rapid degradation by the ubiquitinproteasome pathway 15 and stimulation of HIV IN strand-transfer activity. 6, 16 Overall, the involvement of LEDGF/p75 in several aspects of HIV IN function validates the HIV IN-LEDGF/p75 interaction as a potential target and offers the possibility that perturbation of this interaction could have therapeutic potential.
The binding between LEDGF/p75 and HIV IN requires an approximately 80-residue HIV IN binding domain (p75 IBD) in the C-terminal region of LEDGF/p75, 17 which interacts primarily with residues in the HIV IN catalytic core domain (IN CCD). Structural studies have revealed that the p75 IBD forms a righthanded helical bundle, 18 which associates with a binding pocket formed at the interface of 2 momomers of the IN CCD. 19 p75 IBD residues involved in the interaction are located in the interhelical loop regions of the bundles, and 3 hot-spot amino acid residues, I-365, D-366, and F-406, were identified that are essential for binding and make direct contact with IN CCD residues. The I-365 and D-366 hot-spot residues are contained on an octapeptide that fits into an HIV IN binding pocket. This channel provides a localized site within which small-molecule inhibitors could interact. Ideally, such an inhibitor would target HIV IN-LEDGF/p75 exclusively and therefore avoid potential toxicity issues associated with interfering with the normal functions of LEDGF/p75. 20 In the current study, we describe the development and use of an amplified luminescent proximity homogenous assay (AlphaScreen™) to identify small-molecule inhibitors of the HIV IN-LEDGF/p75 interaction from a compound library of more than 700,000 small molecules arrayed as orthogonal mixtures. False positives resulting from this screening paradigm were eliminated using an his 6 -tagged glutathione S-transferase (GST) protein that mediated bead proximity independent of the HIV IN-LEDGF/p75 interaction. We show that one representative compound identified in this screening campaign can modulate the HIV IN strand-transfer assay. We conclude that the AlphaScreen™ luminescent proximity assay identified a class of HIV IN-LEDGF/p75 interaction inhibitors with potential value as novel regulators of HIV integration.
MATERIALS AND METHODS

Materials
All general biochemical reagents were obtained from Sigma-Aldrich (St Louis, MO) and Fisher Scientific (Pittsburgh, PA). Reagents for AlphaScreen™ assays including the glutathioneconjugated donor beads and Ni-chelate-coupled acceptor beads and 384-well ProxiPlates were purchased from PerkinElmer (Boston, MA). Oligonucleotides SD1) 5′Cy5-ATGTGGAAA-ATCTCTAGCA3′, SD2) 5′Cy5-ACTGCTAGAGATTTTCCAC-AT3′, SA1) 5′ACAGGCCTGCACGCGTGCG3′-biot, and SA2) 5′CGACGCGTGCTA-GGCCTGT3′-biot were purchased from Integrated DNA Technologies (Coralville, IA). The recessed strand donor (SD) DNA was prepared by annealing SD1 and SD2, and the strand acceptor (SA) DNA was prepared by annealing SA1 and SA2. Annealing was carried out by mixing the oligonucleotides at 100 μM in 50 mM Tris (pH 7.6), 10 mM MgCl 2 , 1:1; heating to 90 °C; and slowly cooling to room temperature.
Protein expression plasmids
A human LEDGF/p75 gene cDNA clone was obtained from Origene (Rockville, MD) and used for PCR amplification of the LEDGF/p75 gene and the LEDGF region encoding residues 347-471, which contains the p75 IBD domain (residues 347-429). This enlarged version of the IBD domain was used for protein purification purposes. 18, 19 The PCR products encoding LEDGF/p75 or residues 347-471 were cloned into pGEX-6P-3 (GE HealthCare, Piscataway, NJ) for expression of full-length LEDGF/p75 fusion protein or the p75 IBD fusion protein, in which glutathione S-transferase gene is fused at the N- 
Protein expression and purification
For production of full-length LEDGF/p75 or p75 IBD, cultures of pGEX-6p-3 transformed BL21 (DE3) bacterial cells were grown at 30 °C to an optical density at 600 nm (OD 600 ) of 0.9 and then induced with 0.5 mM isopropyl-beta-D-thiogalactopyranoside (IPTG) for 2 h at 30 °C. After induction, the cells were harvested by centrifugation, and the cell pellets were frozen at -80 °C before further processing. For protein purification, the frozen cell pellet were resuspended in lysis buffer A (50 mM Tris-HCI, pH 7.2, 500 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride) supplemented with complete EDTA free protease inhibitor cocktail (Roche, Indianapolis, IN ) and lysed by microfluidization. Cell lysates were cleared by centrifugation for 30 min at 40,000 rpm in a Ti45 rotor and then loaded onto glutathione columns (GST-Bind Resin; Novagen, San Diego, CA). After protein binding, the columns were extensively washed with buffer B (50 mM Tris-HCI, pH 8.0, 500 mM NaCl, and 1 mM DTT) and fusion proteins were eluted using buffer B supplemented with 20 mM reduced glutathione (pH 8.0). Pooled LEDGF-containing fractions were then dialyzed against a storage buffer (25 mM HEPES pH 7.3, 500 mM NaCl, 1 mM DTT). For the full-length protein, the GST-tag was removed by overnight digestion at 4 °C with 10 U of PreScission Protease per milligram of protein. Cleaved protein was diluted 4× with 25 mM HEPES pH 7.3 to reduce the salt concentration and loaded onto a HiTrap SP-Sepharose column (GE Healthcare), followed by elution with a linear gradient of NaCl from 0.125 to 1 M. Fractions containing cleaved p75 protein were pooled and concentrated in storage buffer and frozen at -80 °C.
His 6 -tagged IN CCD proteins were produced in BL21 (DE3) bacterial cells that had been transformed with pET15b-IN-CCDsol expression plasmids. For induction of protein expression, cells were incubated at 37 °C to an OD 600 of 1.0 and induced by addition of 1 mM IPTG for 4 h at 24 °C. IN CCD protein were purified using a protocol adapted from published reports. 21, 22 For purification, induced cell cultures were harvested as above, resuspended in lysis buffer (1 M NaCl, 20 mM HEPES pH 7.3, 10% glycerol [v/v], 2 mM β-ME, 0.1% n-octylglucoside) and disrupted with a micro fluidizer. Cell lysates were cleared, adjusted to 30 mM imidazole, and mixed with prewashed Fast Flow Ni chelate resin (GE HealthCare) for 1 h with rotation. The Ni chelate resin was preequilibrated in buffer A (30 mM imidazole, 25 mM HEPES, pH 7.3, 2 M NaCl, 10% glycerol, 2 mM β-ME) before protein binding. After protein binding, the Ni chelate resin was collected on columns and washed with Buffer A until an absorbance baseline at 280 nm was reached. Proteins were eluted with Buffer E (250 mM imidazole, 25 mM HEPES pH 7.3, 1 M NaCl, 10% glycerol, 2 mM β-ME), and pooled fractions were separated by size exclusion chromatography through a Sephadex 200 (XK50/100) preequilibrated in 25 mM Tris, pH 7.5, 0.5 M NaCl, 5 mM DTT.
AlphaScreen™ ™ assay
The HIV IN-LEDGF/p75 AlphaScreen™ was developed as a 3-step procedure for high-throughput screening. For the assay, 2.5-μl aliquots of test compounds, resuspended in 10% DMSO, were first predispensed on a 384-well ProxiPlate. Then 5 μl of IN CCD, in 1.25× assay buffer (25 mM HEPES, pH 7.3, 150 mM NaCl, 1 mM DTT, 2 mM MgCl 2 , 0.1% bovine serum albumin [BSA]) was added to a final concentration of 10 nM, after which the assay plates were incubated for 30 min at room temperature. The remaining components in 1.25× assay buffer were then added in 5 μl and included p75 IBD protein (final 10 nM), glutathione donor beads (final 2.5 μg/ml), and Ni-chelate acceptor beads (final 2.5 μg/ml). Following a 60-min room temperature incubation under subdued light conditions (less than 100 Lux), the assay plates were analyzed with an EnVision multilabel plate reader (PerkinElmer, Boston MA).
AlphaScreen™ ™ assay equilibrium time course
Serial 2-fold dilutions of the IN CCD and p75 IBD binding partners (final concentration 5-40 nM) were made in assay buffer (25 mM HEPES, pH 7.3, 150 mM NaCl, 1 mM DTT, 2 mM MgCI 2 , 0.1% BSA). Prior to the protein-protein interaction, the IN CCD and p75 IBD dilutions were preincubated with Nichelate acceptor beads or glutathione donor beads, respectively, at room temperature for 20 min in the dark. Equal 30-μl volumes of each protein-bead combination were then mixed with 15 μl of 10% DMSO, and at the time points indicated, 12.5-μl aliquots were transferred to 384-well ProxiPlates. Signals were read immediately on the EnVision plate reader.
Library screening for HIV IN-LEDGF/p75 interaction inhibitors
Screening was carried out on a BioCel Automated Workcell (Velocity11, Menlo Park, CA), allowing the timed transfer of plates between workstations using an integrated 360°high-speed robotic plate handler. The compound library (2 μg/ml individual compound concentrations) was formatted using an 8 × 8 orthogonal mixing protocol, with each compound appearing twice on each plate in separate mixtures; this provides an expedited process for hit identification. 23 The reaction was carried out in buffer containing (final concentrations) 25 mM HEPES, 2 mM MgCl 2 , 150 mM NaCl, 1 mM dithiothreitol, and 1 mg/ml BSA, pH 7.6. Assay plates were prepared containing 2.5 μl of test compound mixture (8 compounds per pool, 2 μg/ml compound concentration) in 2% DMSO. Purified HIV IN-CCD (1.99 ng in 5 μl) was added, and the reaction was incubated for 30 min at room temperature. The binding reaction was started with the addition of a mix containing 5.18 ng purified p75 IBD plus 31.25 ng Nickel Chelate AlphaScreen™ acceptor beads plus 31.25 ng GSH AlphaScreen™ donor beads (in 5 μl). After incubation for 2 h at room temperature in the dark, the plates were analyzed using an EnVision multilabel plate reader.
A library counterscreen was carried out as described above, replacing purified HIV IN CCD and p75 IBD with 10 nM his 6tagged GST protein.
Strand-transfer assay with HIV IN and LEDGF/p75
The fluorescence resonance energy transfer (FRET)-based strand-transfer protocol was adapted from Wang and others. 24 , and plates were incubated at 37 °C for 1 h. Ten microliters of 12.5 nM SA DNA was then added per well, and plates were incubated at 37 °C for 2 h. The beginning titration concentration for wt IN and p75 in the final 25-μl assay volume was 120 nM and for SD DNA was 50 nM. Twenty-five microliters of detection buffer (20 mM EDTA, 1 M NaCl, 1 mg/ml BSA, and 0.05% Brij-35) containing 2 nM Europium-labeled streptavidin (PerkinElmer, EU-W8044) was added to each well, and plates were incubated at room temperature for 18 h. Plates were read on an EnVision 2100 multilabel reader, and fluorescence was measured using an excitation wavelength of 340 nm and emission wavelengths at 665 nm and 615 nm using a dichroic mirror BB-UV. The FRET ratio for 665 nm/615 nm was calculated.
Data analysis
Data from nonscreening experiments were analyzed using Prism 2.0b (GraphPad, San Diego, CA). Data from screening experiments were analyzed using an Oracle-based proprietary data management system developed by Schering-Plough Research Institute New Lead Discovery. Integration of data with specific compounds is managed by the system through tracking of compound transfers to and from bar-coded plates. The robustness of the assay data was estimated by calculation of the Z′ factor as described. 25 
RESULTS
As described in the Introduction section, a binding pocket present at the interface of 2 IN CCD monomers is an important structural feature required for the protein-protein interaction between HIV IN and LEDGF/p75. 19 We designed the AlphaScreen™ assay to target this binding pocket using IN CCD and p75 IBD fusion proteins. The IN CCD protein used contained HIV IN residues 50-212 fused with an N-terminal his 6 -tag and incorporated the F185K HIV IN mutation to improve protein solubility. 26 IN(F185K) was previously shown to interact effectively with the p75 IBD. 19 The p75 IBD component used for the AlphaScreen™ assay was a fusion of LEDGF/p75 residues 347-471, containing the 80-aminoacid residue integrase binding domain (347-429), joined at the Nterminal to GST. All of the recombinant proteins used for assay development were affinity purified to >90% as determined by NuPAGE 10% Bis-Tris gel electrophoresis (results not shown). For AlphaScreen™ assays, Ni-chelate-coupled acceptor beads and glutathione-conjugated donor beads were used to bind the his 6tagged IN CCD proteins and GST/p75 IBD fusion proteins, respectively.
IN CCD/p75 IBD AlphaScreen™ ™ assay development
The appropriate concentration ratio of the IN CCD and p75 IBD binding partners for the AlphaScreen™ was determined using a fixed concentration of IN CCD (50 nM) titrated against increasing concentrations of the p75 IBD (0-200 nM). Maximum AlphaScreen™ signals were detected using 50 nM p75 IBD, and no further increase in the maximal signal was detected at up to a 4-fold higher concentrations of p75 IBD (Fig. 1A) . These data suggest that a 1:1 ratio of the protein components is needed for an optimal assay signal, which is consistent with the reported cocrystal structure of IN CCD-p75 IBD, in which an IN CCD dimer was found to be complexed with a pair of monomeric p75 IBD molecules. 19 Further assay development was carried out to establish robust signal-to-noise ratios and linear reaction kinetics, and to minimize assay cost, it involved determination of optimal concentrations of each assay component. Preliminary experiments demonstrated that signal-to-noise ratios (>100) could be generated over a wide range of bead concentrations using fixed concentrations of the p75 IBD and IN CCD protein components (data not shown). We therefore chose a concentration of 2.5 μg/ml of both donor and acceptor beads because this still provided an acceptable signal output and a lower cost per well. To determine the optimal concentrations of the IN CCD and p75 IBD protein partners we measured AlphaScreen™ output at various concentrations of p75 IBD and IN CCD, using a 1:1 ratio, and measured signal strength over time (Fig. 1B) . Linear reaction kinetics over a 2-h incubation were observed at protein concentrations between 5 and 20 nM. No increase in signal at concentrations greater than 20 nM occurred, suggesting that binding sites on either the donor and/or acceptor beads had been saturated. Based on the results of this experiment, we selected a 10-nM concentration of the IN CCD and p75 IBD binding partners for the final assay conditions. The final assay condition for HTS is described in detail in the Materials and Methods section. To bias the assay for small molecules that target the IN CCD dimer binding pocket, IN CCD (10 nM) was first preincubated with compound in 10% DMSO at room temperature. After compound preincubation, the remaining components of the assay, including p75 IBD, Ni-chelate acceptor beads, and glutathione-conjugated donor beads, were added to the assay plates and incubated for a minimum of 1 h at room temperature, after which the signal was measured.
Counterscreen assay
We developed an AlphaScreen™ counterscreen assay, using a his 6 -tagged GST protein, to identify compounds that merely interfered with this assay format. Our counterscreen simulates the primary screening assay, bringing the donor and acceptor beads together to generate an AlphaScreen™ signal but without the IN CCD and p75 IBD protein binding partners. Compounds that inhibit the signal in this assay likely represent nonspecific inhibitors that could reduce assay signal by singlet oxygen quenching, inner filter effects, or interference with protein coupling to the assay beads.
Assay validation
To demonstrate that the AlphaScreen™ signal output was the result of an authentic interaction between the IN CCD and p75 IBD, we tested the binding defective p75 IBD/D366N and IN CCD(W131E). Figure 2A demonstrates that when the IN CCD and p75 IBD/D366N were used in the AlphaScreen™, no signal above baseline was detected at any concentration tested. Similarly, when increasing concentrations of p75 IBD and the binding-defective IN CCD(W131E) were titrated against the beads, no AlphaScreen™ signal above baseline was detected (Fig. 2B) . These data are consistent with pull-down experiments (results not shown) demonstrating that the output signal detected in the AlphaScreen™ assay results from the specific protein-protein interaction between the IN CCD and p75 IBD.
To further validate the assay for identification of inhibitors of the IN CCD-p75 IBD interaction, we used full-length LEDGF/p75 as a competitive inhibitor and an anti-CCD polyclonal antibody in an attempt to blockade the IN CCD binding pocket. Figure 3A shows that full-length LEDGF/p75, as expected, efficiently inhibited the IN CCD-p75 IBD interaction with an IC 50 of 6 nM. Interestingly, the anti-CCD antibody also inhibited the AlphaScreen™ signal generated by the IN CCD-p75 IBD interaction with an IC 50 of 41 nM (Fig. 3B) . A reduction of the AlphaScreen™ signal was not observed when rabbit IgG was used as a control. Because reference compounds that inhibit the HIV IN-LEDGF/p75 interaction are not available, the LEDGF/p75 or the anti-IN CCD antibody can be used as positive control compounds for the assay. We next tested the effectiveness of the counterscreen assay for detection of compounds that could interfere with protein coupling to the glutathione-coupled donor beads or Ni-chelate acceptor beads. Figure 3C demonstrates that imidazole interferes with the AlphaScreen™ signal in both the IN CCD-p75 IBD assay and the his 6 -tagged GST protein counterscreen assays with EC 50 s of 1.8 mM and 2.7 mM, respectively. Glutathione inhibited the AlphaScreen™ signal in both assays with an EC 50 of 29 μM in the p75 IBD-IN CCD assay and 22 μM in the counterscreen assay (Fig. 3D) . These results demonstrate that the counterscreen assay can effectively identify compounds that could inhibit coupling of the test proteins to the donor or acceptor beads.
Library screening for p75/integrase antagonists
The optimized IN CCD-p75 IBD binding assay was used to evaluate a random compound library for inhibitors of protein binding. The compound library was arrayed in orthogonal pools, 23 with 8 compounds per mixture. Orthogonal pairs were contained on the same assay plates; thus, each 384-well plate contained 1280 compounds plus validating standards and controls. Hits were identified as compounds that showed greater or equal to 50% inhibition in both pools; pools showing greater or equal to 50% inhibition in only 1 well were identified as false positives. Figure  4A demonstrates that the screening assay generated a robust response through the entire screening campaign. The median Z′ factor for the plates involved in the effort was calculated to be 0.84, reflecting the high signal/noise achieved in the assay. Individual compounds were selected and activity confirmed in separate assays, carried out as ranging 5-point IC 50 determinations run on 2 separate days. These data were used to calculate a hit rate of 0.25%. To ensure that selected compounds inhibited the IN CCD-p75 IBD binding reaction, the top 500 compounds were tested for the ability to inhibit the AlphaScreen™ signal generated using the his 6 -tagged GST protein counterscreen. Although a significant number of compounds inhibited the AlphaScreen™ signal nonspecifically, Figure 4B shows that more than 90 compounds exhibited a greater than 5-fold selectivity for the binding reaction, with 7 compounds exhibiting a greater than 10-fold selectivity for the binding reaction. 
Validation of an IN CCD-p75 IBD inhibitor compound in the HIV strand-transfer assay
Finally, we asked whether the compounds identified from this screen were able to modulate the activity of full-length integrase proteins. Two clinically important HIV therapeutics, raltegravir and elvitegravir, are active in HIV IN strand-transfer assays. We therefore tested the ability of one of the compounds identified from the AlphaScreen™ protein interaction assay to modulate this validated preclinical assay. This assay uses fluorescence to follow the ability of integrase to join a double-stranded oligonucleotide substrate, which mimics the 3′ end of the HIV LTR, into an acceptor duplex oligonucleotide. Figure 5A shows that integrase alone can catalyze this process but that inclusion of LEDGF/p75 in this biochemical assay increases the reaction by more than 50%. Thus, we expected that a compound that blocks the interaction between HIV IN and LEDGF/p75 would decrease activity by about 50%. To our surprise, Figure 5B shows that compound 1 inhibits the strand-transfer assay completely, with an IC 50 = 1.6 μM. This result confirms that the AlphaScreen™ protein interaction assay identified a compound that could modulate the activity of the full-length integrase complex and is highly effective in blocking an important biochemical activity of this complex.
DISCUSSION
In this study, we investigated the interaction of HIV integrase with the cellular cofactor LEDGF/p75 as a potential target for novel antivirals. We chose to use truncated forms of the 2 target proteins to simplify the assay and to bias for compounds that specifically disrupted at the IN CCD-p75 IBD interface. Because the D366N hot-spot mutation abrogates binding between both the truncated forms and the full-length equally effective in the two assays; = compounds 5-fold more effective in the p75/integrase binding assay; = compounds 10-fold more effective in the p75/integrase binding assay. HIV IN and LEDGF/p75 proteins, 19 it was rational to assume that compounds that inhibited the interaction of the truncated forms could also block binding between the full-length proteins. Our analysis of the truncated polypeptides showed that the proteins interacted in the expected manner and were sensitive to inactivating mutations p75 IBD/D366N and IN CCD(W131E). We used these protein constructs to develop an AlphaScreen™ assay that maintained specific binding by all criteria we tested: 1) the signal was dose and time dependent (Fig. 1) versus added protein, 2) the signal required active IN CCD and active p75 IBD (Fig. 2) , and 3) the signal was blocked by added recombinant LEDGF/p75 protein (Fig. 3A) and by added integrase antibody (Fig. 3B) .
The IN CCD/p75 IBD AlphaScreen™ assay was used for high-throughput screening of a library of more than 700,000 small molecules. To speed up the screening process, the compound library (2 μg/ml individual compound concentrations) was formatted using an 8 × 8 orthogonal mixing protocol, with each compound appearing twice on each plate in separate mixtures. 23 We found that although progressing through the screening campaign was faster, the inclusion of 8 compound mixtures in assay wells generated a significant number of AlphaScreen™ false positives. We controlled for these false hits, the presumed result of exacerbated singlet oxygen quenching and inner filter effects at high organic compound concentration in the library mixtures, by screening hits using an AlphaScreen™ reaction mediated by a his 6 -tagged GST control protein. Any compounds inhibiting the signal from this protein interaction-independent assay was considered a false positive and eliminated from further consideration (see Fig. 4) . Overall, about 100 compounds exhibited greater than 5-fold selectivity for the IN CCD-p75 IBD binding assay compared with the counterscreen.
We next sought to determine whether hit compounds specific for the IN CCD-p75 IBD interaction could affect the strand-transfer assay carried out using full-length proteins. These studies are important prerequisites for cellular studies of optimized lead compounds. We expected that these compounds would have a significant but partial effect on the strand-transfer assay, as previous studies showed that inclusion of the LEDGF/p75 protein to the strand-transfer assay stimulated activity. 6, 16 We expected that eliminating the HIV IN-LEDGF/p75 interaction would result in activity consistent with the system lacking LEDGF/p75. However, we were surprised when addition of 1 compound specific for the IN CCD-p75 IBD interaction blocked the strand-transfer activity completely ( Fig. 5B) with an IC 50 of 1.6 μM. We hypothesize from this result that our compound binds to the integrase protein and affects the ability of HIV IN both to bind LEDGF/p75 and to complete the strand transfer. This would be consistent with our initial speculations based on the structural studies of this interaction: The clefts within the IN CCD that interacts with loop structures on p75 IBD provide the best chance for small-molecule binding and are the most likely targets for small-molecule inhibitors. Our initial assumption was that binding within this cleft would sterically block this interaction. Interestingly, attempts to sterically affect the strand-transfer assay with antibodies generated against the IN CCD have proved unsuccessful (data not shown). However, small peptides representing the interhelical loops of the IBD, which interact with the HIV IN binding pocket, have been shown to block HIV IN catalytic function, possibly by shifting the oligomeric state of HIV IN from the dimeric DNA binding form to a tetrameric form unable to bind DNA. 27 It is possible that the compounds that we have identified use a similar mechanism and shift the oligomeric state of HIV IN; however, further characterization is required. Finally, it is interesting to note that the quinolone lead compound used to initiate the development of the clinical integrase inhibitor elvitegravir had the same potency (IC 50 = 1.6 μM) as our new compound in a strand-transfer assay. 28 In conclusion, we have used a protein-protein interaction screen to identify chemotypes that target the interaction of HIV integrase with the cellular targeting factor LEDGF/p75. Using the AlphaScreen™ amplified proximity luminescence platform and 2 truncated protein targets, we have successfully identified several chemotypes specific for blocking this interaction. We show that a member of this series is able to completely block strand-transfer assay activity. We suggest that this class of compounds that targets this novel HIV integrase complex may serve as an important adjunct to current therapies.
